Citations

Showing 10 of 108015 citations.

The $64,000 question
Keller, A. Scott, Schiavo, Dante , Wingo, Majken T. , Ernste, Floranne C. , Sánchez, William , Sanchez, William

Mayo Clinic

Journal of Hospital Medicine | December 24, 2014 | Volume: 10 | Issue: 2 | Pages: 112-115

10.1002/jhm.2304 | PMID 25537658 Get It

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Choueiri, Toni K. , Figueroa, David J. , Fay, André P. , Liu, Yuan , Gagnon, Robert , Deen, Keith C., Benson, Peter, Ho, Thai H. , Pandite, Lini , Souza, Paul de , Powles, Thomas, Motzer, Robert J. , Signoretti, Sabina , Carpenter, Christopher , Ho, Thai , Motzer, Robert J , Choueiri, Toni K

Mayo Clinic

Clinical Cancer Research | December 24, 2014 | Volume: 21 | Issue: 5 | Pages: 1071-1077

10.1158/1078-0432.ccr-14-1993 | PMID 25538263 Get It

Abstract Purpose: The interaction of programmed death-1 ligand (PD-L1) with its receptor (PD-1) on T cells inactivates antitumor immune responses. PD-L1 expression has been associated with poor outcomes in renal cell carcinoma (RCC) but has not been investigated in advanced RCC patients receiving VEGF-targeted therapy. Experimental Design: Formalin-fixed paraffin-embedded specimens were collected at baseline from patients in the COMPARZ trial. Tumor cell PD-L1 expression by IHC was evaluated using H-score (HS). Dual PD-L1/CD68 staining was used to differentiate PD-L1 tumor expression from tumor-associated macrophages. Intratumor CD8-positive T cells were quantified morphometrically. Associations between biomarkers and survival were investigated using the log-rank test. Results: HS data were available from 453 of 1,110 patients. Sixty-four percent of patients had negative PD-L1 expression (HS = 0). Patients with HS > 55 (n = 59, 13%) had significantly shorter overall survival (OS) than those with HS ≤ 55 in both pazopanib and sunitinib arms (median 15.1 vs. 35.6 and 15.3 vs. 27.8 months, respectively, P = 0.03). In both arms, median OS was shortest in patients with HS > 55 and intratumor CD8-positive T-cell counts > 300 (9.6 and 11.9 months with pazopanib and sunitinib, respectively). Median OS in patients with HS ≤ 55 and CD8-positive T-cell counts ≤ 300 was 36.8 and 28.0 months with pazopanib and sunitinib, respectively. Progression-free survival results were similar to OS results. Conclusions: Increased tumor cell PD-L1, or PD-L1 plus tumor CD8-positive T-cell counts, were associated with shorter survival in patients with metastatic RCC receiving VEGF-targeted agents. These findings may have implications for future design of randomized clinical trials in advanced RCC. Clin Cancer Res; 21(5); 1071–7. ©2014 AACR.
Pediatric Atopic Dermatitis and Associated Morbidities
Davis, Dawn Marie R. , Davis, Dawn

Mayo Clinic

JAMA Dermatology | December 23, 2014 | Volume: 151 | Issue: 2 | Pages: 152

10.1001/jamadermatol.2014.3128 | PMID 25535698 Get It

Opioid induced hyperalgesia: A focus on opioid use in chronic pain
Cunningham, Julie L.

Mayo Clinic

Mental Health Clinician | December 23, 2014 | Volume: 2 | Issue: 12 | Pages: 395-397

10.9740/mhc.n155462 Get It

Opioids are a well-established treatment option for chronic pain. However, opioid therapy is associated with many side effects, including opioid induced hyperalgesia (OIH). This article reviews studies which have evaluated OIH in chronic pain patients on opioids.
Ten‐year history of erythematous nodules on the lower extremities
Collins, Jeffrey W. , Lehman, Julia S. , Lehman, Julia S

Mayo Clinic

International Journal of Dermatology | December 23, 2014 | Volume: 54 | Issue: 1 | Pages: 21-23

10.1111/ijd.12596 | PMID 25534404 Get It

Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice
Perschbacher, Katherine J , Smestad, John , Peters, Justin P. , Standiford, Miranda M., Đenić, Aleksandar , Wootla, Bharath , Warrington, Arthur E. , Rodriguez, Moses , Maher, L. James, Perschbacher, Katherine, Wootla, Bharath , Denic, Aleksandar , Rodriguez, Moses , Smestad, John

Mayo Clinic

Nucleic Acid Therapeutics | December 23, 2014 | Volume: 25 | Issue: 1 | Pages: 11-19

10.1089/nat.2014.0515 | PMID 25536292 Get It

DNA aptamer oligonucleotides and their protein conjugates show promise as therapeutics in animal models of diseases such as multiple sclerosis. These molecules are large and highly charged, raising questions about their biodistribution and pharmacokinetics in mammals. Here we exploit the power of quantitative polymerase chain reaction to accurately quantitate the tissue distribution of 40-nucleotide DNA aptamers and their streptavidin conjugates after intraperitoneal injection in mice. We show remarkably rapid distribution to peripheral tissues including the central nervous system. Modeling of tissue distribution data reveals the importance of DNA aptamer sequence, 3′ modification, and protein conjugation in enhancing tissue exposure. These data help to interpret the previously observed effectiveness of aptamer conjugates, as opposed to free aptamers, in stimulating central nervous system remyelination in a mouse model of multiple sclerosis.
Thoracoscopy for Internal Mammary Node Dissection of Metastatic Breast Cancer
Jaroszewski, Dawn E. , Ewais, MennatAllah M., Pockaj, Barbara A.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | December 23, 2014 | Volume: 25 | Issue: 2 | Pages: 135-138

10.1089/lap.2014.0563 | PMID 25535887 Get It

Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910
Pisansky, Thomas M. , Hunt, Daniel , Gomella, Leonard G. , Amin, Mahul B. , Balogh, Alexander G., Chinn, Daniel M., Seider, Michael J. , Duclos, Marie , Bauman, Glenn , Gore, Elizabeth , Rotman, Marvin, Lukka, Himanshu, Shipley, William U. , Dignam, James J., Rosenthal, Seth A. , Bauman, Glenn S, Gore, Elizabeth M, Rotman, Marvin Z, Lukka, Himanshu R, Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | December 23, 2014 | Volume: 33 | Issue: 4 | Pages: 332-339

10.1200/jco.2014.58.0662 | PMID 25534388 Get It

PurposeTo determine whether prolonged androgen suppression (AS) duration before radiotherapy improves survival and disease control in prostate cancer.Patients and MethodsOne thousand five hundred seventy-nine men with intermediate-risk prostate cancer were randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total) or to 28 weeks of AS followed by radiotherapy with an additional 8 weeks of AS (36 weeks total). The trial sought primarily to detect a 33% reduction in the hazard of prostate cancer death in the 28-week assignment. Time-to-event end points are reported for up to 10 years of follow-up.ResultsThere were no between-group differences in baseline characteristics of 1,489 eligible patients with follow-up. For the 8- and 28-week assignments, 10-year disease-specific survival rates were 95% (95% CI, 93.3% to 97.0%) and 96% (95% CI, 94.6% to 98.0%; hazard ratio [HR], 0.81; P = .45), respectively, and 10-year overall survival rates were 66% (95% CI, 62.0% to 69.9%) and 67% (95% CI, 63.0% to 70.8%; HR, 0.95; P = .62), respectively. For the 8- and 28-week assignments, 10-year cumulative incidences of locoregional progression were 6% (95% CI, 4.3% to 8.0%) and 4% (95% CI, 2.5% to 5.7%; HR, 0.65; P = .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI, 4.0% to 7.7%) and 6% (95% CI, 4.0% to 7.6%; HR, 1.07; P = .80), respectively; and 10-year prostate-specific antigen–based recurrence cumulative incidences were 27% (95% CI, 23.1% to 29.8%) and 27% (95% CI, 23.4% to 30.3%; HR, 0.97; P = .77), respectively.ConclusionExtending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes. A lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival. The schedule of 8 weeks of AS before radiotherapy plus 8 weeks of AS during radiotherapy remains a standard of care in intermediate-risk prostate cancer.
Associations Between Inflammation and Cognitive Function in African Americans and European Americans
Windham, B. Gwen , Simpson, Brittany , Lirette, Seth T. , Bridges, J. M. , Bielak, Lawrence F. , Peyser, Patricia A. , Griswold, Michael , Mosley, Thomas H., Kullo, Iftikhar J. , Turner, Stephen T. , Mosley, Thomas H., Lirette, Seth

Mayo Clinic

Journal of the American Geriatrics Society | December 23, 2014 | Volume: 62 | Issue: 12 | Pages: 2303-2310

10.1111/jgs.13165 | PMID 25516026 Get It

Objectives To examine associations between specific inflammatory biomarkers and cognitive function in African Americans (AAs) and European Americans (EAs) with prevalent vascular risk factors. Design Cross‐sectional analysis using generalized estimating equations to account for familial clustering; standardized β‐coefficients, adjusted for age, sex, and education are reported. Setting Community cohort study in Jackson, Mississippi, and Rochester, Minnesota. Participants Genetic Epidemiology Network of Arteriopathy (GENOA)–Genetics of Microangiopathic Brain Injury (GMBI) Study participants. Measurements Associations between inflammation (high‐sensitivity C‐reactive protein (CRP), interleukin (IL)‐6, soluble tumor necrosis factor (TNF) receptor 1 and 2 (sTNFR1, sTNFR2)) and cognitive function (global, processing speed, language, memory, and executive function) were examined in AAs and EAs (N = 1,965; aged 26–95, 64% women, 52% AA, 75% with hypertension). Results In AAs, higher sTNFR2 was associated with poorer cognition in all domains (global: −0.11, P = .009; processing speed: −0.11, P < .001; language: −0.08, P = .002; memory: −0.09, P = .008; executive function: −0.07, P = .03); sTNFR1 was associated with slower processing speed (−0.08, P < .001) and poorer executive function (−0.08, P = .008); higher CRP was associated with slower processing speed (−0.04, P = .024), and higher IL6 was associated with poorer executive function (−0.07, P = .02). In EA, only higher sTNFR1 was associated with slower processing speed (−0.05, P = .007). Associations were not found between cognition and sTNFR2, CRP, or IL6 in EA. Conclusion In a population with high vascular risk, adverse associations between inflammation and cognitive function were especially apparent in AAs, primarily involving markers of TNFα activity.
Spatial and Time-Course Thermodynamics During Pulmonary Vein Isolation Using the Second-Generation Cryoballoon in a Canine In Vivo Model
Takami, Mitsuru , Misiri, Juna, Parker, Kay D., Johnson, Susan B., Sarmiento, Ray I., Packer, Douglas L. , Lehmann, H. Immo

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 23, 2014 | Volume: 8 | Issue: 1 | Pages: 186-192

10.1161/circep.114.002137 | PMID 25532529 Get It

Background— Thermodynamics in the left atrium–pulmonary vein (PV) junction, phrenic nerve, and esophagus during PV isolation (PVI) using the second-generation cryoballoon are not known. Methods and Results— Twenty dogs underwent PVI using second-generation cryoballoon. Ablations were performed for ≤2 deliveries based on PVI without a bonus freeze. Inner balloon, balloon surface, and tissue temperatures were monitored during cryoablation. The tissue thermocouples were placed on the epicardial surface of the left atrium–PV junction, as well as on the phrenic nerve and within the esophagus. A total of 259 cryoballoon and 229 tissue tissue thermocouples profiles during 53 cryoablations of 40 PVs were analyzed. Acutely, PVI was achieved in 36 of 40 PVs (90%). Conductive tissue cooling spread radially from the balloon–left atrium–PV contact point. The lowest tissue temperatures were dependent on the distance of the tissue thermocouples to the balloon surface ( r =0.85; P <0.001). In addition, blood flow leaks around the balloon had a warming effect on the balloon and tissue temperature profiles. Chronic isolation (mean, 48±16 days) was achieved in 27 of 36 PVs (75%). In 8 of 9 acutely isolated but with chronic reconnection PVs, the blood flow leak location was concordant with chronic reconnection gap. Although only 1 esophageal ulcerated lesion was observed, neither phrenic nerve palsy nor severe PV stenosis was seen in any dogs. Conclusions— Variance in tissue thermodynamics during cryothermal ablation depends on the distance from balloon and peri-balloon blood flow leaks. This information may be useful for successful PVI without severe complications.